Condition: Prostate Cancer · Organoid · Sponsor: Tianjin Medical University Second Hospital
This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans.
This description comes directly from the study's public registry record.
Haitao Wang, Ph.D · +86-022-88326385 · peterrock2000@126.com
Jinhuan Wang, Ph.D · +86-022-88326610 · wjhhappy2008@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical Unversity Second Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Medical Unversity Second Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06536725